The political rhetoric surrounding embryonic stem-cell science reveals a widespread misconception of how medical products are created.

Abuse of the tort system by trial lawyers is driving safe drugs from the market and patients from mainstream medicine.

A new study in the Journal of the American Medical Association has concluded that there's an extra 13 auto accident deaths attributable to Income Tax Day (i.e., generally April 15, but which falls on April 17 this year). This is a drop in the bucket compared to the actual carnage that might be reasonably attributed to paying taxes in America.

Perhaps it's the sweet California air, but the pervasive (though not universal) pessimism in biopharma these days is really bumming me out.  Consequently, I'd like to discuss three potential responses to difficult industry problems.

By next year, about two-thirds of American physicians will be working as salaried employees of large groups and hospitals. This movement has been underway for years. Over the last decade, the number of independent physicians was falling by about 2% a year. But these trends are now accelerating. 

Last month, the Drug Enforcement Administration abruptly revoked the narcotics license held by the distributor Cardinal Health, preventing that firm from shipping prescription pain drugs to thousands of Florida pharmacies and hospitals. It's the latest tactic in the DEA's struggle to stem the illicit use of prescription painkillers like OxyContin and Vicodin.

Provision of health care in developing regions is not keeping pace with rapid economic growth.